Drugs for COVID-19

Lecanemab-irmb (Leqembi – Biogen/Eisai), an IV amyloid beta-directed monoclonal antibody, has received accelerated approval from the FDA for treatment of Alzheimer's disease. The label states that treatment with Leqembi should be initiated in patients with mild cognitive impairment (MCI) or mild dementia, the population in which the drug was initiated in clinical trials. Lecanemab is the second IV amyloid-beta directed monoclonal antibody to be approved for this indication; aducanumab (Aduhelm) was approved in 2021 and has the same restrictions on treatment initiation.1,2

...  Continue reading
Coming Soon
Drugs for Hypothyroidism
Semaglutide (Wegovy) for Weight Loss in Adolescents
Deucravacitinib (Sotyktu) for Plaque Psoriasis
Live Fecal Microbiota (Rebyota) for Prevention of CDI